Glenn Heller, PhD

Attending Biostatistician

Glenn Heller, PhD

Attending Biostatistician
Glenn Heller, PhD


New York University

Current Research Interests

Dr. Heller’s current research interests include the design and analysis of phase 2 clinical trials, the analysis of survival data, and the investigation of predictive accuracy measures. For the analysis of phase 2 studies, he has developed a test statistic that adjusts for patient risk when the patient population is heterogeneous. This approach is applicable in basket trials, where multiple patient populations are treated under a single protocol. In survival analysis, he has developed discrimination and explained variation predictive accuracy measures.  These metrics, applied to risk models with survival data, are used as a tool in clinical decisions.  In addition, he has developed methods to evaluate the improvement in risk classification measures due to the inclusion of new biomarkers. Dr. Heller is involved in the design and analysis of laboratory and clinical studies emanating from the Departments of Medicine, Pediatrics, and Surgery.

Research papers



Selected peer-reviewed publications:

Heller G, A modified net reclassification improvement statistic. Journal of Statistical Planning and Inference. 2023. 227: 18-33.

Devlin SM, Heller G. Concordance probability as a meaningful contrast across disparate survival times. Statistical Methods in Medical Research. 2021. 30: 816-825.

Heller G. The added value of new covariates to the Brier score in Cox survival models. Lifetime Data Analysis. 2021. 27: 1-14.

Devlin SM, Gönen M, Heller G. Measuring the temporal prognostic utility of a baseline risk score. Lifetime Data Analysis. 2020. 26: 856-871.

Heller G, Seshan VE, Moskowitz CS, Gonen M. Inference for the difference in the area under the ROC curve derived from nested binary regression models. Biostatistics. 2017. 18: 260-274.

Visit PubMed for a full listing of Glenn Heller’s journal articles

Pubmed is an online index of biomedical articles maintained by the U.S. National Library of Medicine and the National Institutes of Health.


Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Glenn Heller discloses the following relationships and financial interests:

No disclosures meeting criteria for time period

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].

View all disclosures